Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery ...

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.